We are live on ! Find out more
SLN icon

Silence Therapeutics
SLN

7 hedge funds and large institutions have $39.4M invested in Silence Therapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

17% more funds holding

Funds holding: 6 → 7 (+1)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

1.02% less ownership

Funds ownership: 7.56% → 6.53% (-1%)

85% less capital inflows, than outflows

Capital inflows: $1.26M | Capital outflows: $8.56M

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
1
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$1.06M
2
SG Americas Securities
SG Americas Securities
New York
+$174K
3
Morgan Stanley
Morgan Stanley
New York
+$25.1K

Top Sellers

Rank Fund Capital Flow
1
Lombard Odier Asset Management (USA)
Lombard Odier Asset Management (USA)
New York
-$7.53M
2
Consonance Capital Management
Consonance Capital Management
New York
-$1.04M

SLN Hedge Fund Activity: Q3 2021 in Review

7 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2021, worth a combined $39.4M — down 30% from $56.4M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new SLN positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was William Blair & Company, opening a new position worth an estimated $1.06M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $7.53M.

  • 7 institutional investors held Silence Therapeutics (SLN) as of Q3 2021, up from 6 in Q2 2021.
  • Funds reported $39.4M of Silence Therapeutics stock for Q3 2021, down 30% quarter-over-quarter.
  • 1 fund opened new Silence Therapeutics positions in Q3 2021 and 0 closed out, a net change of +1 holder.
  • The largest Silence Therapeutics buyer in Q3 2021 was William Blair & Company, an estimated $1.06M added.
  • The largest Silence Therapeutics seller in Q3 2021 was Lombard Odier Asset Management (USA), an estimated $7.53M sold.

Based on aggregated 13F filings for Q3 2021.